U.S. flag
        An official website of the United States government
          Here’s how you know

      Official websites use .gov
                A
                .gov
                website belongs to an official government organization in the United States.
          Secure .gov websites use HTTPS
                A lock
                  (
                  
                  )
                   or
                  https://
                   means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.Search
                Menu
    
                      Información en Español
                      Search NINDSSearch NINDS
            

            Main navigation
  

        
              Health Information
                                     Toggle Health Information Dropdown
                                Disorders
                Clinical Trials
                Patient & Caregiver Education
                Public Education
                Support Resources
                Funding
                                     Toggle Funding Dropdown
                                Find Funding Opportunities
                About Funding
                Preparing Your Application
                After You Submit
                Determining Your Funding Likelihood
                Manage Your Award
                NINDS Small Business Program
                Training & Career Development
                Current Research
                                     Toggle Current Research Dropdown
                                Coronavirus and NINDS
                Focus on Disorders
                Focus on Tools & Topics
                Research Funded by NINDS
                Research at NINDS
                Scientific Resources
                Trans-Agency Activities
                News & Events
                                     Toggle News & Events Dropdown
                                Events
                News
                Director's Messages
                About NINDS
                                     Toggle About NINDS Dropdown
                                Who We Are
                What We Do
                Job Opportunities 
 Home
                                Current Research
                        Focus on Disorders
SHARE: Focus on Alzheimer's Disease and Related Dementias
video

Webinar: Open and Planned NINDS Alzheimer’s Disease-Related Dementias (ADRD) Funding Opportunities

Join us to learn about current and planned funding opportunities led by the NINDS ADRD program. When: Tues., April 23, 2024 at 1:00 PM ET


  Image
              Brain Graphic
What is AD/ADRD?

Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD) refers to the most common forms of dementia. Dementia likely affects more than 6 million people in the U.S. and more than 55 million people worldwide. Currently, there are no known treatments to prevent or stop the progression of dementia. The toll on individuals, caregivers and society is enormous and will increase as the population ages unless effective interventions are developed. NINDS collaborates with NIH’s National Institute on Aging (NIA), the lead NIH Institute for Alzheimer’s disease (AD) research and for NIH's response to the National Plan to Address Alzheimer’s Disease, to establish research priorities and fund biomedical research to decrease the burden of dementia on individuals, families, and communities.

While AD is the most common dementia diagnosis, ADRDs share many cognitive and pathological features with and can be difficult to distinguish from AD. In fact, more often than not, patients with a clinical diagnosis of Alzheimer’s disease have different mixtures of brain pathologies, complicating both the diagnosis, as well as treatment. A special video testimonial to raise awareness of the disease burden on patients with AD/ADRD and their caregivers titled “Voices of AD/ADRD” was presented at theNINDS ADRD Summit 2022, and can be viewed here:


  
**The ADRDs include:**

Frontotemporal degeneration (FTD)
	Lewy body dementia (LBD)
	Vascular contributions to cognitive impairment and dementia (VCID)
	Multiple-Etiology Dementias (MED)

Going forward, NINDS and NIA will continue to partner in AD/ADRD research planning and implementation, and we urge the research community to join in our efforts to accelerate scientific progress toward reducing the enormous burden and cost of dementia.

Funding Opportunity Announcements

Planned and Current Notices of Funding Opportunity (NOFOs)



Currently Active Funding Opportunities

Investigating Distinct and Overlapping Mechanisms in TDP-43 Proteinopathies, including in LATE, FTD, and other ADRDs (R01 - Clinical Trial Not Allowed) PAR-24-148 -****This initiative aims to establish deeper mechanistic insight and causal relationships between TDP-43 pathology and phenotypic outcomes, as well as mechanistic interactions between TDP-43 and other ADRD-relevant co-pathologies that may impact its regulation and function. Additionally, this concept aims to compare TDP-43 proteinopathies, including limbic-predominant age-related TDP-43 encephalopathy (LATE), with or without Alzheimer’s disease neuropathologic change (AD-NC), and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP), to further understand distinct and overlapping mechanisms in these syndromes. **Due dates:** June 04, 2024 and October 04, 2024 **Contact PO:**Linda McGavern

Mechanistic Investigations into ADRD Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed)  PAR-24-147–****The goal of this initiative is to investigate relevant Alzheimer’s Disease Related Dementias (ADRD) co-pathologies (e.g., tau, alpha-synuclein, TDP-43, TMEM106B, vascular), with optional risk factors and co-morbidities, in the same model system to identify cellular and molecular mechanisms of how multi-pathology interactions drive worsening neurodegenerative processes and ADRD phenotypic outcomes. **Due dates:** June 04, 2024 and October 04, 2024 **Contact PO:**Linda McGavern

Efficacy and Safety of Amyloid-Beta Directed Antibody Therapy in Mild Cognitive Impairment and Dementia with Evidence of Both Amyloid-Beta and Vascular Pathology(U01 - Clinical Trial Required) (RFA-NS-24-013)**-**The goal of this initiative is to encourage the development and implementation of a phase 3 clinical trial to determine the efficacy and safety of FDA approved monoclonal antibody therapy in mixed-etiology dementia populations with evidence of vascular contributions to cognitive impairment and dementia.**Due date:**May 20, 2024**Contact PO:** Rebecca Hommer

NINDS Institutional AD/ADRD Research Training Program (T32 Clinical Trial Not Allowed)(PAR-23-113)- The goal of this initiative is to provide support for institutional research training programs in ADRD. A fundamental goal of this specific program will be for trainees to develop an understanding not only differences and similarities among the various AD/ADRD disorders, but more generally to develop a strong scientific and innovative orientation towards understanding the root mechanistic causes of cognitive impairment and dementia. **Due date:** May 25, 2024 **Contact PO**:Stephen Korn

NINDS Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias (AD/ADRD) Advanced Postdoctoral Career Transition Award to Promote Diversity(K99/R00 Independent Clinical Trial Not Allowed)****(PAR-22-022)- The purpose of this initiative is to enhance workforce diversity by supporting a mentored research experience (K99) followed by independent research (R00) for postdoctoral fellows working in research areas supported by the AD/ADRD Initiative, including research on Alzheimer’s disease, Multiple-Etiology Dementias****(MED), vascular****contributions to cognitive impairment and dementia (VCID), Lewy body dementia (LBD), and frontotemporal degeneration (FTD). The program will provide independent NIH research support during this transition in order to help awardees launch competitive, independent research careers.**Due date:**NIH****Standard dates******Contact PO:**Amelie Gubitz

Development and Validation of Human Cellular Models for Alzheimer's Disease-Related Dementias (ADRD) (R01 - Clinical Trial Not Allowed) RFA-NS-24-032-****The purpose of this initiative is to develop and validate novel, complex, and pathophysiologically relevant human cellular models of Alzheimer’s Disease-Related Dementias (ADRD) to address a gap in currently available models. The cellular model systems would be expected to capture the multi-faceted pathologies and multiple cell types observed in ADRDs. **Due dates:** June 20, 2024 and October 21, 2024 **Contact POs:**Linda McGavernandFrank Shewmaker

Mechanisms of Cognitive Fluctuations in ADRD Populations (R01 - Clinical Trial Optional) RFA-NS-25-014 - This initiative invites research applications focused on understanding the underlying pathophysiology of cognitive fluctuations in people diagnosed with Alzheimer’s Disease- Related Dementias (ADRD). **Due date:** June 24, 2024 **Contact PO:**Debra Babcock

Mechanistic and Hemodynamic Basis of Diffuse White Matter Disease in Vascular Contributions to Cognitive Impairment and Dementia (VCID) (R01 - Clinical Trial Not Allowed) PAR-24-196-****This initiative aims to support hypothesis-testing research to elucidate molecular, cellular and hemodynamic mechanisms that underlie diffuse white matter disease and small vessel disease in the brain and how they may contribute to cognitive decline and dementia. **Due Date:** October 04, 2024 **Contact PO:**Roderick Corriveau

Tools and resources to understand the vascular pathophysiology of in vivo neuroimaging findings in ARIA (U24 - Clinical Trials Not Allowed) RFA-NS-24-034- This initiative to promote the development and distribution of innovative technologies, methods, protocols, and biomedical materials that enhance combined human neuropathology and neuroimaging research aimed at understanding the vascular pathogenesis and pathophysiology of anti-Aβ monoclonal antibody (mAb) induced Amyloid Related Imaging Abnormalities (ARIA). **Due date:** May 31, 2024 **Contact PO:** Carlos Faraco

**Notice of Special Interest (NOSI): Administrative Supplements to Promote Diversity for NINDS ADRD Awardees NOT-NS-24-071 -** This initiative is to encourages eligible NINDS awardees in the AD/ADRD research community to apply for administrative supplements in response to PA-23-189, "Research Supplements to Promote Diversity in Health-Related Research," or any reissues of this announcement through the expiration date of this Notice. **Expiration Date:** February 15, 2027 **Contact PO:** Amber McCartney

**Protective strategies to reduce Amyloid Related Imaging Abnormalities (ARIA) after anti-Aβ immunotherapy (R01 - Clinical Trial Not Allowed) PAR-24-198****-** This initiative is to support mechanistic investigations to better understand the cellular and molecular mechanisms that underlie brain blood vessels responses to passive anti-beta-amyloid immunotherapy that result in amyloid-related imaging abnormalities (ARIA). **Due date:**October 04, 2024**Contact PO:** Francesca Bosetti

**Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed) PAR-24-203****-** This initiative is to solicit applications that propose studies in animal, cell culture, and/or human tissue models to elucidate the mechanisms by which COVID-19 interacts with and/or modulates ADRD-relevant phenotypes. Proposed research must focus on ADRD interactions with COVID-19, for example by incorporating ADRD outcomes, risk factors, pathologies, or relevant comorbidities. **Due Date:**October 04, 2024 **Contact PO:**William P. Daley

Planned Initiatives

We are excited to share with you the research concepts approved by NINDS Council for the fiscal year 2025. Please note that this page will be periodically updated with links when funding opportunities are published. These are also announced via our email listserv (to join the NINDS AD/ADRD listserv, please emailkiara.bates@nih.gov).

Please note that an approved concept listed below does not necessarily indicate an award mechanism or funding allocation is imminent or will happen. The NOFO is only official when published in theNIH Guide.

2025: Previously Published NOFOs Planned for Re-Issue

**Optimization of Genome Editing Therapeutics for ADRDs-** This initiative will support early translational research focused on somatic cell genome editing for Alzheimer's Disease Related Dementias (ADRDs). It is expected that these studies will address the feasibility of using genome editing for therapy development for ADRDs. **Contact PO:**Timothy LaVaute

**Functional Target Validation for Alzheimer's Disease-Related Dementias****-** This initiative is to provide the translational scientific community with increased confidence in the efficacy and safety of novel target to trigger customized therapeutic strategies in ADRDs. **Contact PO:**Pascal Laeng

2025: New NOFO Concepts

**Interaction Between Environmental Factors and Lewy Body Dementia (LBD)-** This initiative is to support research that firmly establishes causal links between environmental factors and Lewy Body formation. This concept aims to reveal the mechanistic basis for how exogenous environmental factors can lead to LBD. **Contac PO:**David Jett

**Mechanistic Investigations into ADRD associated protein structures in biological settings-** This initiative is to support studies proposing to develop and/or utilize methodologies for in-cell structural biology to address questions that have previously been experimentally impossible. The applications are expected to focus on determining AD/ADRD-linked macromolecular structures in native (healthy and pathological) settings. **Contact PO:**George Umanah

**Integrative Multi-Omic Profiling for Lewy Body Dementia-** This initiative is designed to support research to conduct genetic and molecular characterization of LBD. This may include whole genome sequencing, longitudinal bulk-transcriptomics, longitudinal matched plasma, and cerebrospinal fluid (CSF) proteomic analysis, and post-mortem single-cell RNA sequencing, which will be generated and paired with harmonized longitudinal clinical data. **Contact PO:**Christine Swanson-Fischer

**ADRD Risk and Disease Following Nervous System Exposures at Biological Interfaces with the Environment-** This initiative is to support research that aim to by determine how exposures at innervated human surfaces affect ADRD disease mechanisms and phenotypic outcomes. These exposures include toxins and toxic chemicals, viral and other pathogens, and other environmental exposures. **Contact PO:**David Jett

**Including ADRD Biomarker Measures and APOE Genotype Status to ADRD Human Subjects Research Studies-** This initiative is to provide funding to existing AD/ADRD cohort studies to support the inclusion/addition of ADRD fluid-based biomarker measures and APOE genotype status when they are not already utilized in the original study. **Contact PO:**Amber McCartney

**Clinical Trial Readiness to Understand and Develop Solutions to Social, Ethical, and Behavioral Implications (SEBI) Barriers to Health Equity in ADRD-** This initiative is to support research that establishes clinical trial readiness for community-driven interventions to understand and develop solutions to barriers to equity in ADRD outcomes among NIH-designated populations that experience health disparities (HDPs). **Contact POs:**Richard T. Benson,Rebecca HommerandCarolina Mendoza-Puccini

**Safety and Efficacy of Amyloid-Beta Directed Antibody Therapy in Mild Cognitive Impairment and Dementia with Evidence of Both Amyloid-Beta and Lewy Body Dementias**- The goal of this initiative is to encourage the development and implementation of clinical trials to determine the efficacy and safety of amyloid-beta clearing monoclonal antibody therapies in patients with evidence of both Alzheimer’s (amyloid-beta) pathology and clinical LBD, i.e. Parkinson’s disease dementia (PDD) and/or dementia with Lewy bodies (DLB). **Contact PO:**Rebecca Hommer

**IND****-enabling Studies and Clinical Trials for Genome Editing Therapeutics for Alzheimer's Disease and Alzheimer's Disease-Related Dementias -**This initiative support Investigational New Drug (IND) enabling studies for the preparation and submission of an IND for a genome editing therapeutics for ADRD, andoptional small delayed-onset first in human Phase I clinical trial. **Contact PO:**Timothy LaVaute

Training

**NINDS ADRD Advanced Postdoctoral Career Transition Award-** This initiative aims to support a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions (K99) into independent, tenure-track or equivalent faculty (R00) positions in AD/ADRD research areas by providing independent NIH research support during this transition to help awardees establish independent AD/ADRD research programs. **Contact PO:**Amber McCartney

**NINDS ADRD Advanced Postdoctoral Career Transition Award to Promote Diversity****-**The purpose of this initiative is to enhance workforce diversity by supporting a mentored research experience (K99) followed by independent research (R00) for postdoctoral fellows working in research areas supported by the AD/ADRD Initiative, including research on Alzheimer’s disease, mixed etiology dementias (MED), vascular contributions to cognitive impairment and dementia (VCID), Lewy body dementia (LBD), and frontotemporal degeneration (FTD). The program will provide independent NIH research support during this transition to help awardees launch competitive, independent research careers. **Contact PO:**Amelie GubitzandLauren Ullrich

Published Funding Opportunities for Fiscal Year 2024

RE-ISSUES

Early-Stage Therapy Development for Alzheimer's Disease-Related Dementias (ADRD)****(R61/R33 - Clinical Trial Not Allowed) -****This initiative will encourage early-stage development of novel small molecule or biologic therapeutics for ADRD. This initiative will support research to enable competitive follow-on applications that meet the entry criteria for the Blueprint Neurotherapeutics Network, Blueprint Biologics, or other similar later-stage translational programs. **Contact PO:**Rebecca Roof

Optimization of Genome Editing Therapeutics for Alzheimer's Disease-Related Dementias (ADRD)(U01 - Clinical Trials Not Allowed) (RFA-NS-24-009)**-**This initiative will support early translational research focused on somatic cell genome editing for Alzheimer's Disease Related Dementias (ADRDs). It is expected that these studies will address the feasibility of using genome editing for therapy development for ADRDs. **Contact PO:**Timothy LaVaute

Blood Brain Barrier Response to Antibodies Targeting Beta-Amyloid****(PAR-23-140) - This initiative is designed to promote discovery of cellular and molecular mechanisms that underlie brain blood vessels responses to passive anti-beta-amyloid immunotherapy that result in amyloid-related imaging abnormalities. The goal is to establish an understanding of molecular mechanisms that can be targeted to protect the BBB, and thus the brain blood vessels, during therapeutic interventions that target beta-amyloid. **Contact PO:**Roderick Corriveau

Assessment of TBI-related ADRD Pathology Related to Cognitive Impairment and Dementia Outcomes(U01 - Clinical Trial Not Allowed) (RFA-NS-24-003) - This initiative will support applications for a multisite study to comprehensively characterize the neuropathological features associated with neurodegeneration and neurocognitive decline in persons with a history of traumatic brain injury (TBI). To further advance research in the area, broad sharing of clinical and neuropathological data will be a critical feature of this initiative including developing a digital resource for distribution and sharing of assessed neuropathological tissue. **Contact PO:**Nsini Umoh

Center without Walls for PET Ligand Development for Alzheimer's disease-related dementias (ADRDs)****(U19 - Clinical Trial Optional) - The purpose of this initiative is to support a multi-center program that will apply innovative and interdisciplinary approaches to identify and validate PET radioligands for ADRD-related targets (e.g., tau, FUS, TDP43, alpha-synuclein, etc.) and pathways (e.g., neuroinflammation, autophagy, mitochondria, etc.).  Collaborations with investigators overseeing brain bank resources and/or those overseeing existing ADRD-related resources and clinical infrastructure are encouraged. **Contact PO:**Debra Babcock

TRAINING

Administrative Supplements to Promote Diversity for NINDS AD/ADRD Awardees (NOT-NS-21-047)- This initiative is to encourages eligible NINDS awardees in the AD/ADRD research community to apply for administrative supplements in response to PA-23-189, "Research Supplements to Promote Diversity in Health-Related Research," or any reissues of this announcement through the expiration date of this Notice. **Contact PO:**Amber McCartney

NEW CONCEPTS

Validating digital health technologies for monitoring biomarkers in ADRD clinical trials****(R61/R33 - Clinical Trials Optional) (RFA-NS-24-026) - This initiative is to enable partnerships between academics and companies that manufacture wearable digital devices (“digital health technologies (DHTs)”) to develop and validate digital biomarkers for use in monitoring biomarkers in Alzheimer's Disease Related-Dementias (ADRD).  **Contact PO:**Carol Taylor-Burds

Role of Environmental Stress in the Health Inequities of Alzheimer's Disease-Related Dementias (ADRD)****(R01 -Clinical TrialNot Allowed)**-** This initiative is to increase our knowledge of how environmental stressors in lower resourced communities impact risk for ADRD.  **Contact PO:**David JettandRichard T. Benson

VCID Center Without Walls for Understanding and Leveraging Small Vessel Cerebrovascular Disease Mechanisms in ADRD (R01 - Clinical Trial Not Allowed)**-**This initiative is to support research that will, in parallel human-based and model-based studies, advance understanding of fundamental mechanisms related to cerebrovascular disease that contribute to dementia risk and outcomes. **Contact PO:**Roderick Corriveau

Using Multimodal Biomarkers to Differentially Diagnose ADRDs for Clinical Trials****(RFA-NS-24-001) - The purpose of this initiative is to enable multi-site clinical validation of a multimodal set of neuroimaging and biospecimen biomarkers to differentially diagnosis three or more similarly presenting neurodegenerative diseases, including at least one of the Alzheimer’s Disease and Related Dementias (ADRDs). As part of the program deliverables, investigators will be required to submit the markers and imaging protocols through the FDA’s Biomarker Qualification Program, and/or as a diagnostic device through CDRH. **Contact PO:**Carol Taylor-Burds

Simultaneous and Synergistic Multi-Target Validation for Alzheimer’s Disease-Related Dementias(R61/R33Clinical Trialnot allowed)**-** The goal of this initiative is to validate multiple targets for future therapy development for ADRDs that better reflect the complexity of disease. Successful grantees should be in position to apply for IGNITE or other similar translational grant mechanisms after the PAR award is complete. **Contact PO:**Rebecca Roof

Mechanistic Investigations into ADRD Multiple Etiology Dementias(PAR-23-211) - This initiative would support investigations with a minimum of two relevant Alzheimer’s Disease Related Dementias (ADRD) co-neuropathologies (e.g., tau, alpha-synuclein, TDP-43, TMEM106B, vascular), with optional risk factors and co-morbidities, to identify interactions and cellular and molecular mechanisms upstream of aggregated protein states and to determine how these early interactive multi-pathology mechanisms drive worsening neurodegenerative processes and clinical phenotypic outcomes. **Contact PO:**Linda McGavern

Investigating Distinct and Overlapping Mechanisms in TDP-43 Proteinopathies, including in LATE, FTD, and other ADRDs****(PAR-23-212) - This initiative would support studies establishing deeper mechanistic insight and causal cellular and molecular relationships between TDP-43 pathology and clinical phenotypic outcomes. Additionally, the initiative would require comparisons between Alzheimer’s Disease Related Dementias (ADRD) TDP-43 proteinopathies, such as limbic-predominant age-related TDP-43 encephalopathy (LATE), with or without Alzheimer’s disease neuropathologic change (AD-NC), and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) to further understand distinct and overlapping mechanisms in these different syndromes. **Contact PO:**Linda McGavern

Neuropathological Interactions Between COVID-19 and ADRD(PAR-23-214)****- This initiative would solicit applications that propose studies in animal, cell culture, and/or human tissue models to elucidate the mechanisms by which COVID-19 interacts with and/or modulates ADRD-relevant phenotypes. Either the model itself or the experimental readouts will be required to incorporate ADRD risk factors, pathologies, or relevant comorbidities. **Contact PO:**William P. Daley

Development & Characterization of Experimental models of post-TBI ADRD(PAR-23-218) - This initiative is designed to support interdisciplinary teams across multiple sites aimed at developing and characterizing a variety of experimental models that can accurately reproduce the neuropathological signatures and clinically relevant neurodegenerative, biochemical, and behavioral TBI-related dementia sequelae and phenotypes as those seen in humans. Successful models will accelerate the identification of factors and mechanistic pathways contributing towards the predisposition, initiation of and development of neurodegenerative dementia post-TBI. Innovative applications reaching beyond the current AD/ADRD animal models are highly encouraged. **Contact PO:**Hibah O. Awwad

Development and Validation of Models for ADRD****(PAR-23-154) -****This initiative would support development and validation of clinically relevant models of Alzheimer’s Disease Related Dementias (ADRD). Cellular and animal models of multiple interacting pathologies, that mimic the multiple interacting risk factors and comorbidities seen in patients, and that advance key molecular pathways in a pathophysiologically relevant context will be supported. New models need to be innovative and address a gap in the currently available models. **Contact POs:**Linda McGavernandRebecca Roof



For NINDS AD/ADRD Payline Information.



NIH Estimates of Funding for Various Research, Condition, and Disease Categories

Research/Disease Areas*
			FY 2020
			FY 2021
			FY 2022
			FY 2023
			(Estimated)
			FY 2024
			(Estimated)Alzheimer's Disease Including
			Alzheimer's Disease Related
			Dementias (AD/ADRD)
			$2,869
			$3,251
			$3,514
			$3,749
			$3,767Alzheimer's Disease
			$2,683
			$3,059
			$3,314
			$3,502
			$3,515Frontotemporal Dementia
			$166
			$164
			$169
			$174
			$177Lewy Body Dementia
			$84
			$113
			$118
			$124
			$124Vascular Cognitive Impairment/Dementia
			$362
			$455
			$445
			$461
			$464*Dollars in millions and rounded

*To learn more about NIH Investment in AD/ADRD, please visit the Categorical Spending site and enter "Alzheimer's Disease Including Alzheimer's Disease Related Dementias".*



NINDS Leads ADRD Research Priority-Setting Planning Efforts

NINDS-led ADRD summits represent a continuous decade long planning effort. ADRD summits occur every three years and respond to the National Plan to Address Alzheimer’s Disease (“National Plan”) that was released in 2012 and updated annually. These Summits set national research recommendations with timelines that reflect critical scientific priorities for research on ADRD. During each ADRD Summit planning process, the established prioritized recommendations are updated, and developed further, under the leadership of the ADRD Summit Steering Committee, which includes a Working Group of the NANDS Council. The Committee solicits input from nationally and internationally recognized dementia-science experts, as well as public and private stakeholders. The resulting recommendations guide ADRD research for the next several years. Links to NANDS Council-approved ADRD Summit Reports are provided below.

Alzheimer's Disease-Related Dementias Summit 2022; Article on research priorities for studying post-TBI AD/ADRD, based on the ADRD Summit 2022

Alzheimer's Disease-Related Dementias Summit 2019

Alzheimer's Disease-Related Dementias Research Summit 2018

Alzheimer's Disease-Related Dementias Summit 2016; Proceedings article summarizing the 2016 Alzheimer's Disease-Related Dementias Summit

Alzheimer's Disease-Related Dementias Research Summit 2015

Contacts

Rod Corriveau | Program Director roderick.corriveau@nih.gov

Sara Dodson | Senior Health Science Policy Analystsara.dodson@nih.gov

Amber McCartney| Scientific Project Manageramber.mccartney@nih.gov

Arvind Shukla|Scientific Program Analystarvind.shukla@nih.gov

Kiara Bates|Program Specialistkiara.bates@nih.gov



Related Topics

AD+ADRD Research Implementation Milestones databaseThe AD+ADRD Research Implementation Milestones database is a research framework detailing specific steps and success criteria towards achieving the goal of theNational Plan to Address Alzheimer's Disease: to treat and prevent AD and ADRDs by 2025. This database includes research milestones and responsive activities for the NIH triennial AD, ADRD, and Dementia Care, Services and Supports research summits.

International Alzheimer's and Related Dementias Research Portfolio
IADRP reports categories of funded research supported by public and private organizations both in the US and abroad all categorized using the Common Alzheimer's and Related Dementias Research Ontology (CADRO)

Alzheimer’s Disease-Related Dementias Summits Current Research
  
    

    Coronavirus and NINDS
                                                              
                    
                                      COVID-19 News & Events
    
            Coronavirus and the Nervous System
    
            ResourcesFocus on Disorders
                                                              
                    
                                      Alzheimer's Disease and Related Dementias
                                                              
                    
                                      Frontotemporal Dementia (FTD)
    
            Lewy Body Dementia (LBD) Research
    
            Mixed-Etiology Dementias (MED) Research
    
            Vascular contributions to cognitive impairment and dementia (VCID)Amyotrophic Lateral Sclerosis
    
            Epilepsy Research
                                                              
                    
                                      Curing the Epilepsies: The Promise of Research
    
            Epilepsy Therapy Screening Program (ETSP)Pain Research
    
            Parkinson's Disease Research
                                                              
                    
                                      Parkinson's Disease: Challenges, Progress, and Promise
    
            Parkinson’s Disease Research Centers of ExcellenceSpinal Cord Injury Research
    
            Traumatic Brain Injury Research
                                                              
                    
                                      NIH Chronic Traumatic Encephalopathy Diagnosis ConferenceUndiagnosed Disease Network
        
  
              
    
            Focus on Tools & Topics
                                                              
                    
                                      Biomarkers Research
                                                              
                    
                                      Biomarker Program FAQs
    
            Myalgic Encephalomyelitis / Chronic Fatigue Syndrome Biospecimen Resource Access Committee (ME/CFS BRAC)Health Disparities Research
    
            Focus on the Neural Exposome
    
            Neural Engineering Research
    
            Neuroethics
    
            Stem Cell Research
        
  
              
    
            Research Funded by NINDS
                                                              
                    
                                      Clinical Research
                                                              
                    
                                      Office of Global Health and Health Disparities
                                                              
                    
                                      HERN Initiative
    
            U.S.-Japan Brain Research Cooperative Program (BRCP)NeuroNEXT
                                                              
                    
                                      NeuroNEXT Clinical SitesNeuroscience Research
                                                              
                    
                                      Fundamental Neuroscience ResearchTranslational Research
                                                              
                    
                                      Active Projects for Partnering
    
            CREATE Bio
                                                              
                    
                                      CREATE Bio Application Support Library
    
            CREATE Bio Contract Resources/Consultants
    
            CREATE Bio Guidance DocumentsDTR Staff Publications about Programs
    
            Innovation Grants to Nurture Initial Translational Efforts (IGNITE Program)
                                                              
                    
                                      IGNITE - Definitions for Key Terms
    
            IGNITE Milestone ExamplesONETOX: Neural Exposome and Toxicology Programs
                                                              
                    
                                      The Neural Exposome
    
            Chemical Threats
    
            Chemical SafetyTranslational Devices
                                                              
                    
                                      Device Frequently Asked Questions
    
            Human Open Research Neural Engineering Technologies (HORNET) initiative
    
            Milestones for Translational Device Cooperative AgreementsUltra-rare Gene-based Therapy (URGenT) Network
                                                              
                    
                                      Current URGenT Projects
    
            URGenT External Consultant Board (ECB) Members
    
            URGenT Project Consultants & ContractsResearch at NINDS
                                                              
                    
                                      Blue Ribbon Panel Review of NINDS Intramural Research Program
                                                              
                    
                                      Blue Ribbon Panel Highlights
    
            Blue Ribbon Panel Roster
    
            Charge to the Blue Ribbon Panel
    
            Executive Summary of the NINDS Blue Ribbon Panel ReviewScientific Resources
                                                              
                    
                                      Animal Models
    
            Cell/Tissue/DNA
    
            Clinical and Translational Resources
    
            Gene ExpressionTrans-Agency Activities
                                                              
                    
                                      CounterACT Program
                                                              
                    
                                      CounterACT Contract Core Resources
    
            CounterACT Publications
    
            CounterACT Scientific Research Contacts
    
            Current CounterACT Researchers & Projects
    
            FDA Guidance Documents
    
            NIH CounterACT Researcher Honors and AwardsICARE: Interagency Collaborative to Advance Research in Epilepsy
    
            Interagency Research Coordinating Committees
    
            NINDS' Role in the HEAL Initiative
                                                              
                    
                                      Early Phase Pain Investigation Clinical Network (EPPIC-Net)
    
            Pain Therapeutics Development Program
    
            Preclinical Screening Platform for Pain (PSPP)Office of Emergency Care Research
                                                              
                    
                                      OECR Funded Awards
    
            Research Involving an Exception from Informed ConsentRigor & Transparency
                                                              
                    
                                      Initiative to Improve Education in the Principles of Rigorous Research
    
            Rigor Champions and Opportunities
                                                              
                    
                                      NINDS Sustainable Transformation of Institutional Research Rigor (STIRR) Initiative
    
            Rigor IconsRigor and Transparency Resources

Did you find the content you were looking for?
  Yes, I did find the content I was looking for



No, I did not find the content I was looking forPlease rate how easy it was to navigate the NINDS website
  Very easy to navigate



Easy to navigate



Neutral



Difficult to navigate



Very difficult to navigateThank you for letting us know! Any other feedback?Submit

This site is protected by reCAPTCHA and the Google Privacy Policyand Terms of Serviceapply.

      Last reviewed on April 17, 2024
        Contact Us
  

        
              Contact NINDS
                Visitor Information
        Related Sites
  

        
              Site Map
                National Institutes of Health
                Department of Health & Human Services
                USA.gov
        Policies
  

        
              Accessibility
                Freedom of Information Act
                Linking Policy
                Privacy Statement
                Vulnerability Disclosure Policy
Follow NINDS On Social Media
          
          National Institutes of Health (NIH)
          9000 Rockville Pike, Bethesda, MD, 20892